Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients

doi:10.3748/wjg.v26.i34.5130

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 34

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8266)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

530

WORD

192

HTML

4408

Figures (1-5)

328

Tables (1-4)

230

Sum=5688

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

649

Download

1929

Sum=2578

Sep 14, 2020 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (36)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Sep 14, 2020; 26(34): 5130-5145
Published online Sep 14, 2020. doi: 10.3748/wjg.v26.i34.5130

Table 2 Baseline demographic, clinical and laboratory characteristics of patients according to golgi protein 73positivity

	GP73-positive (n = 277)	GP73-negative (n = 355)	P value
Age, median (IQR), yr	59 (15)	55 (22)	< 0.001
Sex, male/female, n (%)	169/108 (61/39)	207/148 (58.3/41.7)	0.545
INR, median (IQR)	1.28 (0.36)	1.09 (0.23)	< 0.001
Platelets, median (IQR), x10³/μL	125 (99.3)	180 (113.7)	< 0.001
AST, median (IQR), U/L	59 (67)	40 (44)	< 0.001
ALT, median (IQR), U/L	43 (45)	39 (43)	0.127
γ-GT, median (IQR), U/L	105 (171)	45 (79)	< 0.001
ALP, median (IQR), U/L	111 (80)	85 (66)	< 0.001
Bilirubin, median (IQR), mg/dL	1.9 (3.1)	0.9 (0.9)	< 0.001
Albumin, median (IQR), g/dL	3.4 (1.1)	4.3 (0.9)	< 0.001
AFP, median (IQR), ng/mL	5 (14.4)	3.5 (5)	< 0.001
APRI score, median (IQR)	1.4 (2.1)	0.6 (1)	< 0.001
Fibrosis stage (METAVIR) F0, F1 / ≥ F2, n (%)	4/28 (12.5/87.5)	92/72 (56.1/43.9)	< 0.001
Cirrhosis, yes/no, n (%)	267/10 (96.4/3.6)	183/172 (51.5/48.5)	< 0.001
Decompensation of cirrhosis, yes/no, n (%)	161/106 (60.3/39.7)	65/118 (35.5/64.5)	< 0.001
HCC, yes/no, n (%)	51/226 (18.4/81.6)	28/327 (7.9/92.1)	< 0.001
HCC BCLC stage, 0/A/B/C/D, n (%)	1/12/11/18/9 (2/23.5/21.6 /35.3/17.6)	1/11/11/3/1¹ (3.7/40.7/40.7 /11.1/3.7)	0.029
HCC BCLC stage, 0-A-B/ C-D, n (%)	24/27 (47.1/52.9)	23/4¹ (85.2/14.8)	0.002
HCC dimensions (very early/intermediate/advanced), n (%)	1/19/31 (2/37.3/60.8)	1/13/13¹ (3.7/48.1/48.1)	0.543

¹One missing case because diagnosis set on autopsy. GP73: Golgi protein 73; IQR: Interquartile range; INR: International normalized ratio; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γ-GT: γ-glutamyl transpeptidase; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein; APRI: AST to platelet ratio index; HCC: Hepatocellular carcinoma; BCLC: Barcelona clinic liver cancer.

Citation: Gatselis NK, Tornai T, Shums Z, Zachou K, Saitis A, Gabeta S, Albesa R, Norman GL, Papp M, Dalekos GN. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients. World J Gastroenterol 2020; 26(34): 5130-5145
URL: https://www.wjgnet.com/1007-9327/full/v26/i34/5130.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i34.5130